Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESULT: Frexalimab, Brivekimig, and Rilzabrutinib in FSGS or MCD
NCT06500702Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of frexalimab, brivekimig and rilzabrutinib in focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) (4 arms), sponsored by Sanofi. Primary endpoint: Percent reduction in urine protein to creatinine ratio at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
frexalimabbrivekimigrilzabrutinib
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT06500702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500702.